<DOC>
	<DOCNO>NCT00153608</DOCNO>
	<brief_summary>In trial HLA-A2+ patient WT1 express carcinoma vaccinate peptide leukemia associate antigen WT1 together immunological adjuvant KLH T-helper protein GM-CSF</brief_summary>
	<brief_title>WT1 Peptid Vaccination Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Metastatic cancer , standard treatment option Resected cancer minimal residual disease , standard treatment option WT1 expression HLAA2 Concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>